STOCK TITAN

Mind Medicine Inc - MNMD STOCK NEWS

Welcome to our dedicated news page for Mind Medicine (Ticker: MNMD), a resource for investors and traders seeking the latest updates and insights on Mind Medicine.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Mind Medicine's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Mind Medicine's position in the market.

Rhea-AI Summary
Mind Medicine (MindMed) has entered into a license agreement with Catalent to access Catalent's Zydis orally disintegrating tablet (ODT) technology. This agreement grants MindMed exclusive rights to develop their lead product candidate MM-120 using the Zydis technology. Zydis ODT is a freeze-dried, oral solid dosage form that disperses instantly in the mouth without water. The technology offers advantages such as improved patient compliance and convenience. MindMed aims to develop brain health treatments that can reach patients in need.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.61%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
13.07%
Tags
conferences earnings
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.33%
Tags
conferences
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.28%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.24%
Tags
none
-
Rhea-AI Summary
Mind Medicine (MindMed) Inc.'s Annual General Meeting of Shareholders was adjourned due to lack of quorum. The meeting will resume on June 21, 2023. The company believes deliberate efforts were made to prevent the meeting from being completed. Shareholders are encouraged to vote for all six of the company's director candidates.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.49%
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.17%
Tags
none
-
News
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.12%
Tags
conferences
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.88%
Tags
clinical trial
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.35%
Tags
clinical trial
Mind Medicine Inc

Nasdaq:MNMD

MNMD Rankings

MNMD Stock Data

699.48M
33.10M
2.42%
25.44%
8.32%
Medicinal and Botanical Manufacturing
Manufacturing
Link
Canada
Vancouver

About MNMD

Mind Medicine Inc., also known as MindMed, is a New York-based psychedelic medicine biotech company that develops psychedelic-inspired medicines known as psychoplastogens and therapies to address addiction and mental illness.